Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company dedicated to developing and commercializing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), has announced its participation in the European Respiratory Society (ERS) Congress 2024. The conference, which will be held both online and onsite in Vienna, Austria, from September 7th to 11th, will feature two oral presentations and a poster presentation focused on seralutinib.
“We are excited to share new findings from our Phase 2 TORREY open-label extension study at the ERS Congress,” said Faheem Hasnain, Co-Founder, CEO, and Chairman of Gossamer Bio. “These results highlight the sustained effects of seralutinib beyond 24 weeks of treatment, with continued improvements in clinical outcome measures and biomarkers related to PAH. This data underscores our commitment to advancing seralutinib as a treatment for PAH and PH-ILD.”
Presentations on Seralutinib
- Oral Presentation
- Session Title: Novel Aspects in Pulmonary Hypertension
- Date & Time: September 8th, 2:15pm – 3:30pm CEST
- Presentation Time: 2:25pm CEST
- Location: Lehar 3
- Abstract Number: 1871
- Title: Sustained Benefit with Seralutinib Treatment: A Post-Hoc Analysis of the TORREY Open-Label Extension
- Presenter: Dr. Vallerie V. McLaughlin
- Oral Presentation
- Session Title: Novel Aspects in Pulmonary Hypertension
- Date & Time: September 8th, 2:15pm – 3:30pm CEST
- Presentation Time: 2:30pm CEST
- Location: Lehar 3
- Abstract Number: 1872
- Title: Sustained Effect of Seralutinib on Circulating Biomarkers in the TORREY Phase 2 Open-Label Extension Study
- Presenter: Prof. Hossein-Ardeschir Ghofrani
- Poster Presentation
- Session Title: Novel Aspects in Pulmonary Hypertension Pathobiology
- Date & Time: September 8th, 12:30pm – 2:20pm CEST
- Location: PS-30 in Poster Area
- Abstract Number: 1613
- Title: Reverse Remodeling and Anti-Proliferative Effects of Seralutinib in PAH Precision-Cut Lung Slices and Pulmonary Artery Smooth Muscle Cells
- Presenter: Prof. Soni S. Pullamsetti
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary hypertension. The company aims to be a leader in the field and improve the lives of patients with pulmonary hypertension.
